Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex

Here's What to Expect From Vertex Pharmaceuticals' Next Earnings Report

Vertex Pharmaceuticals is scheduled to post its fourth-quarter results soon, and analysts project a double-digit earnings growth

Barchart

‘We were sitting with our calculator saying “we can afford that!”’ Joy for families as cystic fibrosis drug prices fall within reach

The cost of medication was too high for thousands of CF sufferers around the world. Now a Bangladeshi company is making a generic version that will change lives

The Guardian - UK

Vertex's Gene Therapy Works In Children With Blood Disorders

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Saturday presented data from multiple studies demonstrating the clinical benefits of Casgevy (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is Vertex Pharmaceuticals Stock Underperforming the Nasdaq?

Vertex Pharmaceuticals has underperformed the broader Nasdaq index over the past year. However, Wall Street analysts remain moderately optimistic about its prospects.

Barchart

Vertex Pharmaceuticals Stock: Analyst Estimates & Ratings

Vertex Pharmaceuticals’ stock has trailed behind the broader market, but analysts are still taking a moderately bullish stance about its prospects.

Barchart

Vertex CEO David DeStefano Steps Down After 26 Years

Vertex, Inc. (NASDAQ:VERX) announced on Tuesday that president and CEO David DeStefano will step down from his roles effective November 10, 2025.

Benzinga

Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Vertex Pharmaceuticals is set to post its third-quarter results next month, and analysts project a single-digit earnings drop.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The Best Biotech ETFs to Buy

Biotech ETFs offer investors exposure to the most innovative and growth-oriented industry within the traditionally defensive healthcare sector.

Kiplinger

Building AI-ready finance teams, not just AI tools

AI is revolutionizing finance by empowering tax teams with technology, skills, and a culture shift.

TechRadar

Do Wall Street Analysts Like Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has significantly underperformed the broader market over the past year, yet analysts remain optimistic about the stock’s prospects.

Barchart

These Analysts Slash Their Forecasts On Vertex After Q2 Results

Vertex, Inc. (NASDAQ:VERX) reported weaker-than-expected sales for the second quarter and cut its FY25 sales guidance below estimates on Wednesday.

Benzinga

Weakness In Vertex Stock Seen As Buying Opportunity

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) stock is falling on Tuesday after the company’s pain data overshadowed strong second-quarter earnings.

Benzinga

These Analysts Cut Their Forecasts On Vertex Pharmaceuticals After Q2 Results

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday.

Benzinga

Vertex Pharmaceuticals Stock Dives After Q2 Earnings, Phase 2 Results For VX-993

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported financial results for the second quarter after the market close on Monday. Here’s a rundown of the report.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Vertex Pharmaceuticals Likely To Report Q2 Profit; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will release earnings results for the second quarter, after the closing bell on Monday, Aug. 4.

Barchart

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need to Know

Vertex Pharmaceuticals is all set to release its fiscal second-quarter earnings next month, and analysts project a robust triple-digit earnings growth.

Barchart

How Is Vertex Pharmaceuticals’ Stock Performance Compared to Other Biotech Stocks?

Vertex Pharmaceuticals has outperformed its biotech peers over the past year, yet Wall Street analysts maintain a reasonably optimistic outlook on its future potential.

MarketBeat

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

Get all your
news in one place.

100’s of premium titles.
One news app.

TechRadar

The IT challenge of real-time e-invoicing amid compliance shifts

Kathya Capote Peimbert at Vertex explains the business imperative of real-time e-invoicing amid regulatory changes.

The Guardian - UK

Painkillers without the addiction? The new wave of non-opioid pain relief

Pharma firms are developing drugs that avoid the brain’s opioid receptors to minimise the risks of dependence and overdoses, but not all experts are convinced

Homes & Gardens

It's your last chance to buy one of our all-time favorite Shark upright vacuums in the Walmart sale – I'm a vacuum tester, and it's a seriously worthy upgrade

The Shark Vertex DuoClean PowerFin Upright Vacuum is now heavily discounted and brilliant for busy homes

Barchart

Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?

Vertex Pharmaceuticals has outperformed relative to the healthcare sector over the past year, yet Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Advnture

“We’ve never been limited to traditional categories” – Arc'teryx goes all in on technical mountain running shoes for 2025

2025 brings some exciting new technical runners from the Canadian brand, including a running shoe you can climb in

Barchart

Are Wall Street Analysts Predicting Vertex Pharmaceuticals Stock Will Climb or Sink?

Vertex Pharmaceuticals has lagged behind the broader market over the past year, and Wall Street analysts are cautiously optimistic about the stock’s future.

Salon

Is a new painkiller too good to be true?

Meet suzetrigine, a non-opioid that promises to avoid addiction risk. But some experts say it can't replace opioids

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

Regeneron Pharmaceuticals

61 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.